Inhibition of Mitochondrial Na+-Ca2+ Exchanger Increases Mitochondrial Metabolism and Potentiates Glucose-Stimulated Insulin Secretion in Rat Pancreatic Islets
- Bumsup Lee1,
- Philip D. Miles2,
- Leonardo Vargas1,
- Peng Luan1,
- Susan Glasco1,
- Yulia Kushnareva1,
- Elisabeth S. Kornbrust1,
- Kathryn A. Grako1,
- Claes B. Wollheim3,
- Pierre Maechler3,
- Jerrold M. Olefsky2 and
- Christen M. Anderson1
- 1Division of Metabolic Diseases, MitoKor, San Diego, California
- 2Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, La Jolla, California
- 3Department of Medicine, University Medical Center, Geneva, Switzerland
Abstract
The mitochondrial Na+-Ca2+ exchanger (mNCE) mediates efflux of Ca2+ from mitochondria in exchange for influx of Na+. We show that inhibition of the mNCE enhances mitochondrial oxidative metabolism and increases glucose-stimulated insulin secretion in rat islets and INS-1 cells. The benzothiazepine CGP37157 inhibited mNCE activity in INS-1 cells (50% inhibition at IC50 = 1.5 μmol/l) and increased the glucose-induced rise in mitochondrial Ca2+ ([Ca2+]m) 2.1 times. Cellular ATP content was increased by 13% in INS-1 cells and by 49% in rat islets by CGP37157 (1 μmol/l). Krebs cycle flux was also stimulated by CGP37157 when glucose was present. Insulin secretion was increased in a glucose-dependent manner by CGP37157 in both INS-1 cells and islets. In islets, CGP37157 increased insulin secretion dose dependently (half-maximal efficacy at EC50 = 0.06 μmol/l) at 8 mmol/l glucose and shifted the glucose dose response curve to the left. In perifused islets, mNCE inhibition had no effect on insulin secretion at 2.8 mmol/l glucose but increased insulin secretion by 46% at 11 mmol/l glucose. The effects of CGP37157 could not be attributed to interactions with the plasma membrane sodium calcium exchanger, l-type calcium channels, ATP-sensitive K+ channels, or [Ca2+]m uniporter. In hyperglycemic clamp studies of Wistar rats, CGP37157 increased plasma insulin and C-peptide levels only during the hyperglycemic phase of the study. These results illustrate the potential utility of agents that affect mitochondrial metabolism as novel insulin secretagogues.
Footnotes
-
Address correspondence and reprint requests to Dr. Christen M. Anderson, Metabolic Diseases, MitoKor, 11494 Sorrento Valley Rd., San Diego, CA 92121. E-mail: andersonc{at}mitokor.com.
Received for publication 16 July 2002 and accepted in revised form 23 December 2002.
C.B.W., P.M., and J.M.O. have acted as consultants for MitoKor.
AUC, area under the curve; [Ca4]i, cytosolic calcium; [Ca2+]m, mitochondrial Ca2+; EC50, half-maximally effective concentration; FBS, fetal bovine serum; DCFC-DA, dichlorofluorescein-diacetate; GSIS, glucose-stimulated insulin secretion; IC50, contration causing 50% inhibition; KATP, ATP-sensitive K+; KCN, potassium cyanide; KRB, Krebs-Ringer bicarbonate; mNCE, mitochondrial Na+-Ca2+ exchanger; NCX, plasma membrane sodium-calcium exchanger; ROS, reactive oxygen species.
- DIABETES














